The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells.

Humans Animals Mice Skin Neoplasms Proto-Oncogene Proteins B-raf / genetics Galactosylceramidase / genetics Sphingolipids Proteomics Chromatography, Liquid Tandem Mass Spectrometry Melanoma, Experimental Mutation Cell Line, Tumor Melanoma, Cutaneous Malignant
melanoma proteomics β-galactosylceramidase

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Jun 2023
Historique:
received: 18 05 2023
revised: 13 06 2023
accepted: 20 06 2023
medline: 17 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

β-Galactosylceramidase (GALC) is a lysosomal enzyme involved in sphingolipid metabolism by removing β-galactosyl moieties from β-galactosylceramide and β-galactosylsphingosine. Previous observations have shown that GALC may exert pro-oncogenic functions in melanoma and

Identifiants

DOI: 10.3390/ijms241310555 PMID: 37445731 PMC: PMC10342161
pubmed: 37445731
pii: ijms241310555
doi: 10.3390/ijms241310555
pmc: PMC10342161
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins B-raf EC 2.7.11.1
Galactosylceramidase EC 3.2.1.46
Sphingolipids 0
BRAF protein, human EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Italian Association for Cancer Research
ID : IG Grant n°18493
Organisme : Department of Excellence - DIMET - Università del Piemonte Orientale
ID : AGING Project

Références

Front Mol Biosci. 2021 May 25;8:679584
pubmed: 34113652
Parasitol Int. 2012 Mar;61(1):136-9
pubmed: 21763455
J Mol Neurosci. 2019 Nov;69(3):399-410
pubmed: 31280474
Oncogene. 2004 Mar 25;23(13):2347-56
pubmed: 14743208
Front Oncol. 2020 Apr 07;10:380
pubmed: 32318333
Int J Mol Sci. 2021 Mar 23;22(6):
pubmed: 33806766
Lipids Health Dis. 2021 Oct 31;20(1):150
pubmed: 34717628
Cell Mol Biol Lett. 2021 Dec 11;26(1):52
pubmed: 34895159
Front Med (Lausanne). 2021 Sep 22;8:747333
pubmed: 34631760
Mol Cancer Res. 2023 Jan 3;21(1):36-50
pubmed: 36214668
Cancers (Basel). 2020 Oct 27;12(11):
pubmed: 33121001
Oncotarget. 2017 Oct 31;8(62):106132-106142
pubmed: 29285320
J Transl Med. 2012 Jul 09;10:85
pubmed: 22554099
Cancer Biomark. 2018;22(3):417-426
pubmed: 29758927
Trends Mol Med. 2008 Aug;14(8):361-71
pubmed: 18603472
J Bioenerg Biomembr. 2021 Oct;53(5):621-632
pubmed: 34251584
J Gastrointest Oncol. 2021 Aug;12(4):1905-1926
pubmed: 34532138
Immunotherapy. 2017 Nov;9(14):1185-1198
pubmed: 29067886
J Control Release. 2022 Nov;351:255-271
pubmed: 36165836
Exp Oncol. 2015 Sep;37(3):173-80
pubmed: 26422100
J Cutan Pathol. 2010 Feb;37(2):256-68
pubmed: 19615007
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810334
Cells. 2021 Nov 16;10(11):
pubmed: 34831420
J Proteome Res. 2009 Oct;8(10):4810-22
pubmed: 19705920
Mol Cancer Ther. 2013 Dec;12(12):2760-71
pubmed: 24130051
Br J Cancer. 2020 Jan;122(2):182-193
pubmed: 31819175
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Biol Chem. 2017 Jun 23;292(25):10574-10585
pubmed: 28465351
J Biol Chem. 2007 Jul 6;282(27):19676-84
pubmed: 17456474
Cancer Lett. 2004 Dec 8;216(1):35-42
pubmed: 15500947
Biomed Pharmacother. 2022 Nov;155:113741
pubmed: 36271543
Bioinformatics. 2020 Apr 15;36(8):2628-2629
pubmed: 31882993
Chem Phys Lipids. 1990 Mar;53(2-3):165-75
pubmed: 1970953
J Cell Biochem. 2016 Nov;117(11):2559-69
pubmed: 27012556
Mol Cell Proteomics. 2019 Jun;18(6):1227-1241
pubmed: 30926673
J Invest Dermatol. 2002 Feb;118(2):246-54
pubmed: 11841540
Curr Mol Med. 2016;16(6):533-44
pubmed: 27211800
ACS Chem Biol. 2021 Feb 19;16(2):360-370
pubmed: 33517652
Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188675
pubmed: 34974112
Brain. 2013 Sep;136(Pt 9):2859-75
pubmed: 23983033
J Proteome Res. 2013 Oct 4;12(10):4366-75
pubmed: 23987666
Cancer Immunol Res. 2021 May;9(5):568-582
pubmed: 33727246
Cancer Res. 2020 Nov 15;80(22):5011-5023
pubmed: 32998995
Pharmacol Res. 2022 Aug;182:106302
pubmed: 35691539
Br J Cancer. 2018 Sep;119(6):713-723
pubmed: 30116025
J Oncol. 2022 Oct 26;2022:7854297
pubmed: 36339646
Cancers (Basel). 2022 May 21;14(10):
pubmed: 35626147
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Chem Biol. 2019 Dec;15(12):1232-1240
pubmed: 31740833
Cell. 2019 Sep 19;179(1):236-250.e18
pubmed: 31495571
Cell Death Dis. 2021 Sep 3;12(9):827
pubmed: 34480020
Front Oncol. 2023 Jan 26;12:1061832
pubmed: 36776379
J Dermatol. 2021 Nov;48(11):1772-1779
pubmed: 34459016
Mol Cancer Ther. 2006 Jun;5(6):1493-503
pubmed: 16818508
Eur J Med Genet. 2021 Oct;64(10):104316
pubmed: 34425242
Clin Transl Med. 2021 Jul;11(7):e451
pubmed: 34323402
Front Genet. 2022 Aug 03;13:956314
pubmed: 35991543
J Proteomics. 2016 Aug 11;145:3-10
pubmed: 26921831
Front Genet. 2022 Sep 23;13:1006936
pubmed: 36212146

Auteurs

Davide Capoferri (D)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
ORCID: 0000-0002-1251-8136

Paola Chiodelli (P)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

Marzia Corli (M)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

Mirella Belleri (M)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

Elisa Scalvini (E)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

Luca Mignani (L)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

Jessica Guerra (J)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

Elisabetta Grillo (E)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
ORCID: 0000-0002-8403-0607

Veronica De Giorgis (V)

Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
Center for Allergic and Autoimmune Diseases, University of Piemonte Orientale, 28100 Novara, Italy.

Marcello Manfredi (M)

Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
Center for Allergic and Autoimmune Diseases, University of Piemonte Orientale, 28100 Novara, Italy.

Marco Presta (M)

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Consorzio Interuniversitario Biotecnologie (CIB), Unit of Brescia, 25123 Brescia, Italy.
ORCID: 0000-0002-4398-8376

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Eucaryotes › Animaux › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinases raf › Protéines proto-oncogènes B-raf › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Glycosidases › Galactosidases › Galactosylceramidase › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Lipides › Lipides membranaires › Sphingolipides › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Protéomique › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Chromatographie › Chromatographie en phase liquide › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Spectrométrie de masse › Spectrométrie de masse en tandem › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Tumeurs expérimentales › Mélanome expérimental › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › The Pro-Oncogenic Sphingolipid-Metabolizing...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › The Pro-Oncogenic Sphingolipid-Metabolizing...